FDA Down-Classifies Another App Linked To Apple Watch

Agency finalizes order allowing sponsors to submit 510(k) applications for photoplethysmograph analysis software less than a month after doing same for another Apple-led app.

An Apple Watch measuring heartbeat
AN APPLE WATCH MEASURES A USER'S HEARTBEAT. • Source: Alamy

The US Food and Drug Administration is allowing sponsors to use the 510(k) pathway for photoplethysmograph analysis software two years after the agency authorized using, in an app Apple markets as part of its health suite on its Apple Watch, the analysis which detects blood volume changes in the skin to measure a user’s heart rate and blood volume.

In a final order published the the 4 February Federal Register, the FDA said it codified its decision to...

Welcome to HBW Insight

Create an account to read this article

More from Regulation

NPA On Clock To Continue Challenge To FDA ‘Drug Preclusion’ Policy For Dietary Ingredients

 

FDA rejects NPAs arguments for clarity on when it recognizes start of investigational new drug programs and what constitutes “substantial clinical investigations” for an IND. Clock starts after FDA met twice-extended deadline to provide answers to NPA’s questions in a 2023 petition.

US FDA Facility Inspections, Website Reviews Paused With FY 2026 Budget On Hold

 

Continuing work includes “for cause and certain surveillance inspections of regulated facilities” and “criminal enforcement work and certain civil investigations” as White House mulls layoffs rather than furloughs during federal government shutdown.

‘Lawful’ Marketing Not Necessary For Dietary Ingredients To Beat ‘Drug Preclusion’ Date

 

In change with potential to help supplement firms establish availability of dietary ingredients in US predates their use in drugs, FDA grants argument by NPA and CRN that marketing of ingredients dates to even when they use in supplements may be unlawful under agency regulations.

US Supplement Industry Suffers Setback From FDA In Battle Against Impediments To Innovation

 

FDA responds to trade groups' citizen petitions saying it wouldn’t change its policies for when INDs are registered, dates which could preclude subsequent introductions of dietary ingredients, and what constitutes “substantial clinical investigations” in INDs.

More from Policy & Regulation

US FDA Facility Inspections, Website Reviews Paused With FY 2026 Budget On Hold

 

Continuing work includes “for cause and certain surveillance inspections of regulated facilities” and “criminal enforcement work and certain civil investigations” as White House mulls layoffs rather than furloughs during federal government shutdown.

PAGB: UK NHS Risks Missed Opportunity If Digital Self-Care Not Urgently Prioritized

 
• By 

The NHS App should direct users to trusted, external OTC brand resources where appropriate, says PAGB in its latest report.

‘Lawful’ Marketing Not Necessary For Dietary Ingredients To Beat ‘Drug Preclusion’ Date

 

In change with potential to help supplement firms establish availability of dietary ingredients in US predates their use in drugs, FDA grants argument by NPA and CRN that marketing of ingredients dates to even when they use in supplements may be unlawful under agency regulations.